Aurobindo Pharma’s US facility received a Voluntary Action Indicated classification. The US FDA closed its inspection of the Raleigh manufacturing plant. This classification allows applications for inhalers and other products to proceed. The inspection covered inhaler, dermatology, and transdermal product manufacturing operations. The company’s regulatory filing confirmed the inspection closure and VAI status.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.